These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1161 related articles for article (PubMed ID: 19428882)

  • 1. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.
    Czajka H; Schuster V; Zepp F; Esposito S; Douha M; Willems P
    Vaccine; 2009 Nov; 27(47):6504-11. PubMed ID: 19665608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.
    Rinderknecht S; Michaels MG; Blatter M; Gaglani M; Andrews W; Abughali N; Chandreshekaran V; Trofa AF
    Pediatr Infect Dis J; 2011 Oct; 30(10):e179-85. PubMed ID: 21617573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old.
    Gatchalian S; Tabora C; Bermal N; Leboulleux D; Desauziers E
    Am J Trop Med Hyg; 2004 Mar; 70(3):273-7. PubMed ID: 15031516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.